Nick Pizzie

Introduction

Nick Pizzie is an accomplished finance executive with an extensive career in the pharmaceutical and medical device industries. Born and raised in Somerset, New Jersey, Nick has spent his career building a reputation for delivering financial growth and operational efficiency.

Educational Background

Nick's educational background includes a Master of Business Administration (MBA) from Rutgers University, with a focus on Finance and Supply Chain. This strong foundation in business and finance has been critical to his success in various leadership roles.

Early Career

Nick's career began at Arthur Andersen, where he worked as an auditor from 1997 to 1999. His role involved financial audits, which equipped him with solid financial control and reporting skills. He then moved to Wyeth, serving as an Accounting Manager and in audit from 2000 to 2005. During his time at Wyeth, Nick managed general accounting and played a key role in ensuring the department's compliance with the Sarbanes-Oxley Act. He also designed a forecast model to help increase market share in a test market.

Schering-Plough

From 2005 to 2008, Nick worked at Schering-Plough as a Senior Finance Manager, overseeing financial operations for fifteen plants in the Americas region. He was instrumental in developing network strategies and presenting financial plans to senior management, which undoubtedly honed his skills in financial analysis and forecasting.

Immucor, Inc.

Nick then joined Immucor, Inc. in 2008 as the Senior Finance Director. Over five years, he managed all aspects of accounting and finance, significantly improving inventory accuracy and playing a pivotal role in the acquisition and integration of the LIFECODES business.

Pierre Fabre USA

In 2013, Nick took on the role of Chief Financial Officer at Pierre Fabre USA. During his five-year tenure, he led a team of 27 professionals across various departments including Finance, Accounting, Business Intelligence, and more. Under his leadership, the company's revenue more than doubled, and profitability increased by over 20 points. Nick also executed successful mergers and acquisitions, including the acquisition of Tolak in 2017, and implemented cost-saving initiatives such as reducing third-party logistics costs by 40% and telecom charges by 38%.

Axsome Therapeutics, Inc.

Since May 2018, Nick has been serving as the Chief Financial Officer at Axsome Therapeutics, Inc., a biopharmaceutical company focused on developing therapies for central nervous system (CNS) conditions. Based in New York City, Axsome Therapeutics specializes in providing innovative treatments for CNS disorders with limited options, working to transform approaches to CNS treatment through novel mechanisms of action.

Conclusion

Throughout his career, Nick has demonstrated a keen ability to create and implement effective financial strategies, lead and empower teams, and drive efficiencies and scalability. His expertise in financial analysis, forecasting, budgeting, and compliance makes him a vital asset to the organizations he has served.

Nick Pizzie's journey from an auditor to a CFO of a burgeoning biopharmaceutical company showcases his dedication, expertise, and impact in the financial landscape of the healthcare sector.